Sanofi gets CDSCO marketing nod for RSV treatment Beyfortus in India
Drugmaker, Sanofi India, has received marketing authorisation approval from the Central Drugs Standard Control Organisation (CDSCO) for Beyfortus in India.
Beyfortus is used for the prevention of Respiratory Syncytial Virus (RSV) and Lower Respiratory Tract Disease (LRTD) in newborns and infants.
It is also administered to children up to 24 months of age, who remain vulnerable to severe RSV disease through their second RSV season.
RSV is a highly contagious virus that can lead to serious respiratory illness in infants.
"Prevention of RSV in India is still an unmet medical need. This makes the approval of Beyfortus a landmark moment for Sanofi in India," Sanofi Vaccines (India) General Manager Preeti Futnani stated.
In March 2017, Sanofi and AstraZeneca announced an agreement to develop and commercialise Beyfortus.
Under the terms of the agreement, AstraZeneca leads development and manufacturing activities, and Sanofi leads commercialisation activities and records revenues
Read also: Sanofi Healthcare to infuse Euro 400 million in Hyderabad GCC by 2030
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.